Author

K. Yizhak

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Mehta· 3 shared G. M. Boland· 3 shared M. Sade-Feldman· 3 shared N. Hacohen· 3 shared D. Liu· 2 shared K. T. Flaherty· 2 shared M. Parikh· 2 shared R. J. Sullivan· 2 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Mehta

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy

O.-Y. Revach, A. M. Cicerchia, O. Shorer, B. Petrova, S. Anderson, J. Park, L. Chen, A. Mehta, S. J. Wright, N. McNamee, A. Tal-Mason, G. Cattaneo, P. Tiwari, H. Xie, J. M. Sweere, , K. Yizhak

This study shows that targeting CD38 improves T cell function and restores response to immunotherapy in melanoma models.

bioRxiv · Feb 12, 2024 · PreprintCancer Biology

Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response

J. H. Chen, L. T. Nieman, M. Spurrell, V. Jorgji, P. M. Richieri, K. H. Xu, R. Madhu, M. Parikh, I. Zamora, A. Mehta, C. S. Nabel, S. S. Freeman, J. D. Pirl, C. Lu, C. B. Meador, , N. Hacohen

The paper identifies immune hubs in lung cancer that are associated with better responses to PD-1-blockade immunotherapy and contain stem-like CD8 T cells.

bioRxiv · Apr 4, 2023Immunology

Plasma proteomic biomarkers identify non-responders and reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockade

A. Mehta, M. Rucevic, E. Sprecher, M. Parikh, J. Chem, D. T. Frederick, E. Woods, L. Bi, D. Lieb, L. Hultin-Rosenberg, J. Guess, R. J. Park, A. Schneider, W. Michaud, B. Miao, , G. M. Boland

The paper identifies plasma proteomic biomarkers that predict non-response to PD1 blockade in melanoma patients and links them to tumor microenvironment biology.

bioRxiv · Feb 2, 2022 · PreprintCancer Biology

Alternative splicing of SLAMF6 in human T cells creates a co-stimulatory isoform that counteracts the inhibitory effect of the full-length receptor

E. Hajaj, E. Zisman, S. Tzaban, S. Merims, J. E. Cohen, S. Klein, S. Frankenburg, M. Sade-Feldman, Y. Tabach, K. Yizhak, A. Navon, P. Stepensky, N. Hacohen, T. Peretz, A. Veillette, , M. Lotem

This study identifies an alternative splicing event in SLAMF6 that generates a co-stimulatory isoform, which enhances T cell cytotoxicity and is associated with improved anti-tumor responses in melanoma.

bioRxiv · Aug 21, 2020 · PreprintImmunology